XLV strategy verdict

Health Care Select SPDR (XLV) strategy verdict: The strategy underperforms buy-and-hold on XLV in its observed regime. Across all tickers, the pullback and risky-accumulation strategies beat holding in 89.8% of crash-regime backtests; that edge may not apply here.

Closed trades: 233 of 282 (82.6%) made money in default-settings backtests of the pullback strategy. A win rate counts closed trades only; a position that is still open and down is not in it.

Against buy-and-hold: 11.8% of 553 backtests beat holding XLV over the same dates (65 of 553). The median backtest's gap to holding was -7.8 points a year.

Median return across its backtests: 1% a year for the strategy, against 8.8% a year for buying and holding XLV over the same dates.

Average Sharpe ratio 0.27; average maximum drawdown -24.7%.

Risk level: informed gamble. Dominant regime: modest. History tested: about 28 years.

Backtests are research, not advice. Past results do not predict future returns, and most strategies we test do not beat holding.

What is XLV?

Health Care Select Sector SPDR Fund (XLV) is a State Street sector fund that follows the Health Care Select Sector Index, made up of the health care companies in the S&P 500, such as drug makers, medical equipment firms and health insurers.

Also searched for as: xlv etf, healthcare etf, health care select sector spdr, us health care sector etf, health care sector etf.